Basic Information
| LncRNA/CircRNA Name | LBCS |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | androgen | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, RIP |
| Sample | the human prostate cancer cells LNCaP (ATCC, Manassas, VA, USA), and the CRPC-like cell LNCaP-Bic and LNCaPAI. LNCaP cells, PCa tissues, BPH tissues |
| Expression Pattern | down-regulated |
| Function Description | The expression of Lnc-LBCS was lower in CRPC cells lines and tissues. LBCS downregulation was correlated with higher Gleason Score, T stage and poor prognosis of PCa patients. LBCS overexpression decreases, whereas LBCS knockdown increases, the traits of castration resistance in prostate cancer cells under androgen ablated or AR blocked condition. Moreover, knockdown of LBCS was sufficient to activate AR signaling in the absence of androgen by elevating the translation of AR protein. Mechanistically, LBCS interacted directly with hnRNPK to suppress AR translation efficiency by forming complex with hnRNPK and AR mRNA. |
| Pubmed ID | 31221168 |
| Year | 2019 |
| Title | A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer |
External Links
| Links for LBCS | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |